目的:分析甲状腺功能亢进症（甲亢）患者骨密度与血清骨代谢指标的相关性。方法:选取2018年1月至2019年8月太原钢铁（集团）有限公司总医院收治的甲亢患者30例为甲亢组，选择同期在该院常规体检的健康人30例为对照组，采用双能X线骨密度仪对入选对象进行骨密度测量，采用罗氏化学发光仪测定入选对象的骨代谢指标：25-羟基维生素D［25（OH）D］、血清Ⅰ型前胶原氨基端前肽（PINP）和β-胶原特殊序列（β-CTX）；采用Spearman法分析甲亢患者各部位骨密度与骨代谢指标的相关性。结果:甲亢组患者腰椎1~4椎体［（0.86±0.14）g/cmn 3］、左股骨颈［（0.79±0.07）g/cmn 3］、左髋关节［（0.72±0.10）g/cmn 3］骨密度值均明显低于对照组［（1.28±0.21）g/cmn 3、（1.03±0.18）g/cmn 3、（0.86±0.13）g/cmn 3］，差异均有统计学意义（n t=9.115、6.806、4.675，均n P<0.001）；甲亢组患者中，骨质疏松6例、骨质减少12例、骨质正常12例；对照组中，骨质疏松1例、骨质减少6例、骨质正常23例；两组骨质疏松情况差异有统计学意义（n Z=2.968，n P<0.05）；甲亢组患者血清25（OH）D水平（16.89±4.31）μg/L，明显低于对照组的（24.13±5.48）μg/L，差异有统计学意义（n t=5.688，n P<0.001）；甲亢组患者血清PINP（49.37±10.23）μg/L、β-CTX（774.56±159.67）ng/L，均明显高于对照组的（47.68±6.49）μg/L、（534.32±167.48）ng/L，差异均有统计学意义（n t=45.974、5.687，均n P<0.001）；甲亢组患者第1~4腰椎、股骨颈和全髋关节各部位骨密度与血清25（OH）D水平均呈正相关（n r=0.417、0.396、0.401，均n P<0.05），与血清PINP、β-CTX水平均呈负相关（n r=-0.414、-0.399、-0.432，-0.404、-0.387、-0.412，均n P<0.05）。n 结论:甲亢患者普遍存在骨密度低、骨代谢加快的状况，定期监测甲亢患者的骨密度和血清骨代谢指标，对预防骨质疏松具有重要意义。“,”Objective:To correlate bone mineral density with serum bone metabolism indexes in patients with hyperthyroidism.Methods:Thirty patients with hyperthyroidism who received treatment in the General Hospital of Taiyuan Iron and Steel (Group) Co., Ltd. from January 2018 to August 2019 were included in the hyperthyroidism group. Additional 30 healthy subjects who concurrently received routine physical examination were included in the control group. Bone mineral density in all subjects was measured by dual energy X-ray absorptiometry. Bone metabolism indexes in all subjects were measured using a Roche chemiluminescence instrument: 25-hydroxyvitamin D level [25(OH)D], aminoterminal propeptide of type I procollagen (PINP) and beta-cardiotoxin (β-CTX). Correlation between bone mineral density and serum bone metabolism indexes was analyzed using Spearman method.Results:Bone mineral density in lumbar vertebrae 1-4 [(0.86 ± 0.14) g/cmn 3], left femoral neck [(0.79 ± 0.07) g/cmn 3] and left hip joint [(0.72 ± 0.10) g/cmn 3] in the hyperthyroidism group was significantly lower than that in the control group [(1.28 ± 0.21) g/cmn 3, (1.03 ± 0.18) g/cmn 3, (0.86 ± 0.13) g/cmn 3, n t = 9.115, 6.806, 4.675, all n P < 0.001]. There were 6 cases of osteoporosis, 12 cases of osteopenia and 12 cases of normal bone in the hyperthyroidism group. There was 1 case of osteoporosis, 6 cases of osteopenia and 23 cases of normal bone in the control group. There was significant difference in the number of cases developing osteoporosis between hyperthyroidism and control groups ( n Z = 2.968, n P < 0.05). Serum level of 25(OH)D in the hyperthyroidism group was significantly lower than that in the control group [(16.89 ± 4.31) μg/L n vs. (24.13 ± 5.48) μg/L, n t = 5.688, n P < 0.001]. Serum levels of PINP and β-CTX in the hyperthyroidism group were significantly lower than those in the control group [PINP: (49.37 ± 10.23) μg/L n vs. (47.68 ± 6.49) μg/L; β-CTX: (774.56 ± 159.67) ng/Ln vs. (534.32 ± 167.48) ng/L, n t = 45.974 and 5.687, both n P < 0.001]. In the hyperthyroidism group, bone mineral density at lumbar vertebrae 1-4, left femoral neck and left hip joint was positively correlated with serum level of 25(OH)D ( n r = 0.417, 0.396, 0.401, all n P < 0.05), and it was negatively correlated with serum levels of PINP and β-CTX ( n r = -0.414, -0.399, -0.432, -0.404, -0.387, -0.412, all n P < 0.05).n Conclusion:Hyperthyroidism patients generally have low bone mineral density and accelerated bone metabolism. It is of great significance to regularly monitor bone mineral density and serum bone metabolism indexes in hyperthyroidism patients to prevent osteoporosis.